Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Preferred Stock Liabilities (2018 - 2019)

Endonovo Therapeutics has reported Preferred Stock Liabilities over the past 2 years, most recently at $1.8 million for Q4 2019.

  • Quarterly results put Preferred Stock Liabilities at $1.8 million for Q4 2019, up 17.79% from a year ago — trailing twelve months through Dec 2019 was $1.8 million (up 17.79% YoY), and the annual figure for FY2019 was $1.8 million, up 17.79%.
  • Preferred Stock Liabilities for Q4 2019 was $1.8 million at Endonovo Therapeutics, up from $1.8 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for ENDV hit a ceiling of $1.8 million in Q4 2019 and a floor of $665999.0 in Q1 2018.